Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $96.00

Intra-Cellular Therapies (NASDAQ:ITCIGet Free Report) had its target price hoisted by stock analysts at Mizuho from $82.00 to $96.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price target indicates a potential upside of 32.65% from the stock’s current price.

Several other research analysts also recently commented on the company. The Goldman Sachs Group increased their price objective on Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a research note on Wednesday, April 17th. Royal Bank of Canada restated an “outperform” rating and issued a $86.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 3rd. Canaccord Genuity Group decreased their price objective on shares of Intra-Cellular Therapies from $101.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, February 23rd. TD Cowen lifted their target price on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Finally, Robert W. Baird upped their price target on Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.33.

Read Our Latest Stock Report on Intra-Cellular Therapies

Intra-Cellular Therapies Stock Up 0.5 %

NASDAQ:ITCI opened at $72.37 on Monday. The stock has a market capitalization of $7.01 billion, a PE ratio of -49.57 and a beta of 1.02. Intra-Cellular Therapies has a 52 week low of $45.50 and a 52 week high of $84.89. The stock’s 50-day moving average price is $69.31 and its 200-day moving average price is $64.19.

Intra-Cellular Therapies (NASDAQ:ITCIGet Free Report) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.14. The firm had revenue of $132.10 million for the quarter, compared to analyst estimates of $135.97 million. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The business’s revenue was up 50.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.45) EPS. Sell-side analysts expect that Intra-Cellular Therapies will post -0.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Suresh K. Durgam sold 6,450 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total value of $429,312.00. Following the completion of the sale, the executive vice president now directly owns 16,170 shares of the company’s stock, valued at approximately $1,076,275.20. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Sharon Mates sold 40,712 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $66.50, for a total transaction of $2,707,348.00. Following the completion of the transaction, the chief executive officer now owns 1,050,309 shares of the company’s stock, valued at $69,845,548.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Suresh K. Durgam sold 6,450 shares of Intra-Cellular Therapies stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $66.56, for a total value of $429,312.00. Following the transaction, the executive vice president now directly owns 16,170 shares in the company, valued at $1,076,275.20. The disclosure for this sale can be found here. Insiders have sold a total of 168,487 shares of company stock worth $11,364,950 in the last quarter. Company insiders own 3.40% of the company’s stock.

Institutional Investors Weigh In On Intra-Cellular Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of ITCI. JPMorgan Chase & Co. raised its holdings in shares of Intra-Cellular Therapies by 11.7% in the 1st quarter. JPMorgan Chase & Co. now owns 157,144 shares of the biopharmaceutical company’s stock worth $9,615,000 after purchasing an additional 16,454 shares in the last quarter. Bank of New York Mellon Corp grew its position in Intra-Cellular Therapies by 5.2% in the first quarter. Bank of New York Mellon Corp now owns 385,508 shares of the biopharmaceutical company’s stock worth $23,591,000 after buying an additional 18,999 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in shares of Intra-Cellular Therapies in the first quarter valued at $349,000. PNC Financial Services Group Inc. lifted its position in shares of Intra-Cellular Therapies by 25.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,909 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 1,204 shares during the last quarter. Finally, Natixis Advisors L.P. boosted its stake in shares of Intra-Cellular Therapies by 71.3% during the 1st quarter. Natixis Advisors L.P. now owns 18,165 shares of the biopharmaceutical company’s stock worth $1,112,000 after acquiring an additional 7,558 shares in the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

About Intra-Cellular Therapies

(Get Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

See Also

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.